A

AmyPore

10 employees

AmyPore develops an innovative drug that targets a common mechanism of Alzheimer's and Parkinson's diseases.

Basic info

Industry

biotechnology research

Sectors

molecular dynamics simulations
Biotechnology
lipid rafts
amyloid pores
amyloid oligomers
drug design
gangliosides
Pharmaceutical
molecular neurosciences
lipid-protein interactions
neurodegenerative diseases
Health Care
type 2 diabetes
biological membranes
cholesterol
calcium imaging

Date founded

2018

Funding rounds raised

Total raised

$82K

from 2 investors over 2 rounds

A

AmyPore raised undisclosed on April 3, 2019

Investors: Incubateur inter-universitaire Impulse

A

AmyPore raised $82K on January 1, 2019

Investors: Executive Agency for Small and Medium-sized Enterprises (EASME)

FAQ